GENMAB AS SP.ADR/1/10DK 1 - Asset Resilience Ratio

Latest as of December 2025: 0.00%

GENMAB AS SP.ADR/1/10DK 1 (GE91) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GE91 working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€0.00

≈ $0.00 USD Cash + Short-term Investments

Total Assets

€12.87 Billion

≈ $15.05 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how GENMAB AS SP.ADR/1/10DK 1's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see GE91 total assets.

Liquid Assets Composition Over Time

This chart breaks down GENMAB AS SP.ADR/1/10DK 1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore GENMAB AS SP.ADR/1/10DK 1 strategic investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€0.00	0%
Total Liquid Assets	€0.00	0.00%

Asset Resilience Insights

Limited Liquidity: GENMAB AS SP.ADR/1/10DK 1 maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

GENMAB AS SP.ADR/1/10DK 1 Industry Peers by Asset Resilience Ratio

Compare GENMAB AS SP.ADR/1/10DK 1's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for GENMAB AS SP.ADR/1/10DK 1 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for GENMAB AS SP.ADR/1/10DK 1.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.00%	€0.00 ≈ $0.00	€12.87 Billion ≈ $15.05 Billion	--
2024-12-31	24.54%	€1.57 Billion ≈ $1.83 Billion	€6.39 Billion ≈ $7.47 Billion	-13.06pp
2023-12-31	37.60%	€1.97 Billion ≈ $2.30 Billion	€5.24 Billion ≈ $6.13 Billion	-3.67pp
2022-12-31	41.27%	€1.79 Billion ≈ $2.09 Billion	€4.33 Billion ≈ $5.07 Billion	-0.88pp
2021-12-31	42.15%	€1.58 Billion ≈ $1.85 Billion	€3.75 Billion ≈ $4.38 Billion	--

pp = percentage points

About GENMAB AS SP.ADR/1/10DK 1

F:GE91 Germany Biotechnology

Market Cap

$17.14 Billion

€14.66 Billion EUR

Market Cap Rank

#1627 Global

#353 in Germany

Share Price

€23.80

Change (1 day)

+3.48%

52-Week Range

€17.00 - €29.80

All Time High

€44.40